Ascelia Pharma AB

Orviglance Regulatory Progress

- The FDA review of the New Drug Application (NDA) for Orviglance is progressing according to plan, with a PDUFA date of July 3, 2026. - The NDA submission is supported by a completed development program, including nine clinical studies with 286 patients and healthy volunteers, demonstrating consistent positive efficacy and safety results. -…